申请人:National Research Development Corp.
公开号:US04587240A1
公开(公告)日:1986-05-06
Compounds which are a 1-hydroxypyrid-2-one in which one or more of the hydrogen atoms attached to ring carbon atoms are replaced by a substituent selected from aliphatic acyl, aliphatic amide, aliphatic amine, carboxy, cyano, aliphatic ester, halogen, hydroxy and sulpho groups, alkoxy groups and alkoxy groups substituted by an alkoxy, aliphatic amide, aliphatic amine, aliphatic ester, halogen or hydroxy group, aliphatic hydrocarbon groups and aliphatic hydrocarbon groups substituted by an alkoxy, aliphatic ester, halogen or hydroxy group, but excluding compounds in which said replacement of hydrogen atoms in the compound is effected only by substituents selected from aliphatic hydrocarbon groups, halogen groups and aliphatic hydrocarbon groups substituted by a halogen group, or a salt thereof containing a physiolgically acceptable ion or ions, are of value in the treatment of patients having a toxic concentration of a metal, particularly iron, in the body whilst the iron complexes of such compounds are of value in the treatment of iron deficiency anaemia.
具有1-羟基吡啶-2-酮结构的化合物,其中环碳原子上的氢原子被从脂肪酰基,脂肪酰胺,脂肪胺,羧基,氰基,脂肪酯,卤素,羟基和磺酸基,烷氧基以及被烷氧基,脂肪酰胺,脂肪胺,脂肪酯,卤素或羟基取代的烷氧基取代的取代基所取代,脂肪烃基以及被烷氧基,脂肪酯,卤素或羟基取代的脂肪烃基,但不包括仅通过脂肪烃基,卤素基和被卤素基取代的脂肪烃基所取代的化合物,或者其含有生理上可接受的离子的盐,对于治疗体内有毒浓度的金属,尤其是铁,尤其有价值,而这些化合物的铁络合物对于治疗缺铁性贫血也具有价值。